The historic falls on Wall Street continued to impact the lab industry through late September and early October. For the week ended Oct. 17, 2008, the G-2 Laboratory Index was down 29 percent over the past five weeks and 30 percent so far in 2008. None of the 14 publicly traded labs tracked by the Index showed any growth over the past four weeks. In fact, all except one are down in the double digits compared to the previous four weeks. In addition, Nasdaq and S&P have yet to lift. The Nasdaq is down 36 percent, while the S&P 500 is down 36.38 percent so far in 2008.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

November 2008 - Table of Contents

LIR November 2008 (full PDF issue)

Lab Stocks Level Out After October Plunge; Six Execs Offer Views on Latest Economic Developments

Hospital Referral Expense per Reportable Result Expected to Drop 11% by Year End

Survey Finds Many Starting Salaries for Pathologists Are Between $100k and $250k

Inside the Lab Industry: Lab Execs See Economy Driving More Consolidation, Will Push New Administration for Higher Reimbursement

Response Genetics Teams With NeoGenomics to Expand Cancer Testing Sales Effort

Industry Veterans Plunge Into Dental Mol Dx Market With Launch of OralDNA Labs

High Rates of Test Ordering, Reporting Errors in Physician Offices Highlight Role for Labs

Lab Stocks Dip Sharply; Down 29% Over 5 Weeks, 30% for Year

FDA Threatens LabCorp With Regulatory Action Over OvaSure Claims

Nebraska’s Pathology Services Saves $3k a Year by Paying Customer Service Reps More